Article Text
Statistics from Altmetric.com
Footnotes
Contributors All authors have read and approved the final manuscript and each meets the criteria for authorship established by the International Committee of Medical Journal Editors and verify the validity of the results reported. We confirm that our paper has not been published in its current form or a substantially similar form (in print or electronically, including on a website), that it has not been accepted for publication elsewhere and that it is not under consideration by another publication.
Funding DYG and HE-S are supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center.
Competing interests DYG is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel Helicobacter pylori therapies and has received research support for culture of H. pylori and is the PI of an international study of the use of antimycobacterial therapy for Crohn’s disease. HE-S is a consultant for Phathom Pharmaceuticals regarding novel H. pylori therapies.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.